{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:59:15Z","timestamp":1787237955052,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.hlc.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:28:17Z","timestamp":1748611697000},"page":"753-763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Sacubitril\/Valsartan on Renal Function in Adults With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-1407","authenticated-orcid":false,"given":"Joshuan J.","family":"Barboza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin A.","family":"Le\u00f3n-Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Pasupuleti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4420-2419","authenticated-orcid":false,"given":"Alejandro","family":"Piscoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuani M.","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Valenzuela-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Diaz-Arocutipa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9999-4003","authenticated-orcid":false,"given":"Adrian V.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2025.01.004_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/03007995.2020.1853509","article-title":"Clinical relevance of transient worsening renal function after initiation of sacubitril\/valsartan","volume":"37","author":"Masarone","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.hlc.2025.01.004_bib2","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ehjcvp\/pvab030","article-title":"Renal protection in chronic heart failure: focus on sacubitril\/valsartan","volume":"7","author":"Pontremoli","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.hlc.2025.01.004_bib3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/ndt\/gfz058","article-title":"Chronic kidney disease, heart failure and neprilysin inhibition","volume":"35","author":"Haynes","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.hlc.2025.01.004_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ijcard.2019.06.031","article-title":"Sacubitril\/valsartan for heart failure in adults with complex congenital heart disease","volume":"300","author":"Maurer","year":"2020","journal-title":"Int J Cardiol"},{"issue":"Suppl 1","key":"10.1016\/j.hlc.2025.01.004_bib5","article-title":"Role of sacubitril\/valsartan in the treatment of chronic heart failure with reduced ejection fraction in elderly hypertensives with comorbidity: from clinical trials to real world","volume":"39","author":"Mazza","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.hlc.2025.01.004_bib6","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1093\/eurheartj\/ehab627","article-title":"The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy","volume":"42","author":"Crea","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.01.004_bib7","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2025.01.004_bib8","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/ejhf.1697","article-title":"Evaluation of kidney function throughout the heart failure trajectory \u2013 a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Mullens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2025.01.004_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173444","article-title":"Effects of sacubitril\/valsartan in patients with heart failure and chronic kidney disease: a meta-analysis","volume":"884","author":"Kang","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.hlc.2025.01.004_bib10","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/FJC.0000000000001421","article-title":"Effects of Sacubitril-Valsartan in patients with various types of heart failure: a meta-analysis","volume":"81","author":"Zhang","year":"2023","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hlc.2025.01.004_bib11","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.hlc.2025.01.004_bib12","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.hlc.2025.01.004_bib13","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1002\/sim.7665","article-title":"Multistep estimators of the between-study variance: the relationship with the Paule-Mandel estimator","volume":"37","author":"van Aert","year":"2018","journal-title":"Stat Med"},{"key":"10.1016\/j.hlc.2025.01.004_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jrsm.1460","article-title":"Zero-cell corrections in random-effects meta-analyses","volume":"11","author":"Weber","year":"2020","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.hlc.2025.01.004_bib15","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.hlc.2025.01.004_bib16","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2025.01.004_bib17","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hlc.2025.01.004_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jch.13153","article-title":"Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study","volume":"20","author":"Cheung","year":"2018","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.hlc.2025.01.004_bib19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin Inhibition versus enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.01.004_bib20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.hlc.2025.01.004_bib21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1161\/CIRCULATIONAHA.118.034818","article-title":"Effects of Sacubitril\/Valsartan versus irbesartan in patients with chronic kidney disease","volume":"138","author":"Haynes","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.01.004_bib22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of Sacubitril-Valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.hlc.2025.01.004_bib23","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.01.004_bib24","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.01.004_bib25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2025.01.004_bib26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of Sacubitril\/Valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - results from the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.hlc.2025.01.004_bib27","first-page":"330","article-title":"Entresto (Sacubitril\/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.hlc.2025.01.004_bib28","series-title":"Chronic Heart Failure in Adults: Diagnosis and Management","year":"2018"},{"key":"10.1016\/j.hlc.2025.01.004_bib29","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0735-1097(20)31657-0","article-title":"Cardiovascular and renal outcomes of mineralocorticoid receptor antagonist use in Paragon-HF","volume":"75","author":"Jering","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2025.01.004_bib30","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0735-1097(20)31595-3","article-title":"Worsening renal function, hyperkalemia and hypotension in SACUBITRIL-VALSARTAN VS. Enalapril in HFREF: a meta-analysis","volume":"75","author":"Malik","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2025.01.004_bib31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.mayocpiqo.2020.10.008","article-title":"Renal outcomes in patients with systolic heart failure treated with Sacubitril-Valsartan or angiotensin converting enzyme inhibitor\/angiotensin receptor blocker","volume":"5","author":"Tan","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"10.1016\/j.hlc.2025.01.004_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/3239057","article-title":"Role and mechanism of the renin-angiotensin-aldosterone system in the onset and development of cardiorenal syndrome","volume":"2022","author":"Ma","year":"2022","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"Suppl 4","key":"10.1016\/j.hlc.2025.01.004_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003495-199000394-00004","article-title":"Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function","volume":"39","author":"Ljungman","year":"1990","journal-title":"Drugs"},{"key":"10.1016\/j.hlc.2025.01.004_bib34","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.hlc.2025.01.004_bib35","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/jcpt.13243","article-title":"Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: a meta-analysis of randomized controlled trials","volume":"45","author":"Feng","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl 2","key":"10.1016\/j.hlc.2025.01.004_bib36","article-title":"Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials","volume":"43","author":"Hernandez","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.01.004_bib37","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2025.01.004_bib38","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2025.01.004_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060655","article-title":"Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"12","author":"Tsai","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.hlc.2025.01.004_bib40","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00592-021-01757-z","article-title":"Tandem positive action of SGLT2 inhibitors and ARNI in patients with heart failure","volume":"58","author":"Napoli","year":"2021","journal-title":"Acta Diabetol"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950625000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T13:08:26Z","timestamp":1753880906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950625000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1443950625000289"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2025.01.004","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Sacubitril\/Valsartan on Renal Function in Adults With Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}